19.35
+0.04(+0.21%)
Currency In USD
| Previous Close | 19.31 |
| Open | 19.1 |
| Day High | 19.8 |
| Day Low | 19.02 |
| 52-Week High | 35.84 |
| 52-Week Low | 16.97 |
| Volume | 1.23M |
| Average Volume | 435,290 |
| Market Cap | 558.15M |
| PE | 31.21 |
| EPS | 0.62 |
| Moving Average 50 Days | 20.75 |
| Moving Average 200 Days | 26.58 |
| Change | 0.04 |
If you invested $1000 in Castle Biosciences, Inc. (CSTL) since IPO date, it would be worth $904.21 as of May 03, 2025 at a share price of $19.35. Whereas If you bought $1000 worth of Castle Biosciences, Inc. (CSTL) shares 5 years ago, it would be worth $709.31 as of May 03, 2025 at a share price of $19.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
GlobeNewswire Inc.
Yesterday at 8:30 PM GMT
Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC” FRIENDSWO
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
GlobeNewswire Inc.
Apr 30, 2025 9:00 PM GMT
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery FRIE
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
GlobeNewswire Inc.
Apr 28, 2025 11:00 AM GMT
Castle Biosciences celebrates an incredible milestone — the 200,000th order of the DecisionDx-Melanoma test! This milestone is so much more than a number: it represents 200,000 opportunities to provide clinicians and their patients with more ac